Late results of complementary specific immunostimulation in metastatic prostate carcinoma.
Calculation of the 5-year actuarial survival reveals a clear superiority of a combination of estrogenic hormone therapy with specific immunostimulation as compared to hormone therapy alone. The aim of this investigation was to show that specific immunostimulation complementary to estrogenic hormone therapy can substantially improve the results of the latter. Because of the appreciable side effects of estrogens, we have abandoned them as basic therapy. Today, we combine specific immunotherapy with RH-LH analogs and androgen receptor blockers and hope to attain further improvement of the actuarial survival in metastatic prostate carcinoma.